NDATOPICALCREAM
Approved
Oct 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MENTAX (butenafine hydrochloride) is a topical antifungal cream approved in 1996 for the treatment of dermatophyte infections, including tinea pedis, tinea corporis, and tinea versicolor. Butenafine is a benzylamine antifungal that disrupts fungal cell membrane ergosterol synthesis, providing broad-spectrum antimycotic activity. The product is administered as a topical cream applied directly to affected skin areas.
$0.01BPart D
LOE ApproachingMature product approaching loss of exclusivity with minimal Medicare Part D utilization signals a small, stable brand team focused on generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS
Started Jan 2019
42 enrolled
Tinea Pedis
Career Relevance
Working on MENTAX as a Viatris employee offers limited career growth due to the product's mature, pre-LOE lifecycle stage and minimal linked job openings. Roles are primarily defensive, focused on market maintenance, managed care negotiations, and generic transition planning rather than innovation or market expansion.
Brand Manager
Worked on MENTAX at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.